¹⁸F-fluorodeoxyglucose PET and PET-CT in early detection of cancer recurrent

Early detection of recurrent can improve prognosis and survival of patients with cancer. ¹⁸-fluorodeoxyglucose(¹⁸F-FDG) PET can detect metabolic changes before structural changes. The fused imaging provided by PET-CT can precisely localize the loci and demonstrate the complementary roles of functional and anatomic assessments in the diagnosis of cancer recurrence. In addition to the accurate diagnosis and definition of the whole extent of recurrent cancer, ¹⁸F-FDG PET and PET-CT can impact patients' management.